Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kenneth Alan Freedberg, M.D.

Co-Author

This page shows the publications co-authored by Kenneth Freedberg and Elena Losina.
Connection Strength

14.931
  1. College Campuses and COVID-19 Mitigation: Clinical and Economic Value. Ann Intern Med. 2021 04; 174(4):472-483.
    View in: PubMed
    Score: 0.911
  2. College campuses and COVID-19 mitigation: clinical and economic value. medRxiv. 2020 Sep 05.
    View in: PubMed
    Score: 0.893
  3. Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States. Clin Infect Dis. 2017 10 15; 65(8):1266-1271.
    View in: PubMed
    Score: 0.731
  4. Life expectancy in HIV. BMJ. 2011 Oct 11; 343:d6015.
    View in: PubMed
    Score: 0.482
  5. The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One. 2010 Mar 04; 5(3):e9538.
    View in: PubMed
    Score: 0.431
  6. Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis. 2009 Nov 15; 49(10):1570-8.
    View in: PubMed
    Score: 0.422
  7. Visual screening for malignant melanoma: a cost-effectiveness analysis. Arch Dermatol. 2007 Jan; 143(1):21-8.
    View in: PubMed
    Score: 0.346
  8. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defic Syndr. 2006 Dec 01; 43 Suppl 1:S113-8.
    View in: PubMed
    Score: 0.344
  9. Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire. S Afr Med J. 2006 Jun; 96(6):526-9.
    View in: PubMed
    Score: 0.332
  10. Clinical Outcomes, Costs, and Cost-effectiveness of Strategies for Adults Experiencing Sheltered Homelessness During the COVID-19 Pandemic. JAMA Netw Open. 2020 12 01; 3(12):e2028195.
    View in: PubMed
    Score: 0.227
  11. Clinical Outcomes, Costs, and Cost-effectiveness of Strategies for People Experiencing Sheltered Homelessness During the COVID-19 Pandemic. medRxiv. 2020 Oct 20.
    View in: PubMed
    Score: 0.225
  12. The impact of user fees on uptake of HIV services and adherence to HIV treatment: Findings from a large HIV program in Nigeria. PLoS One. 2020; 15(10):e0238720.
    View in: PubMed
    Score: 0.225
  13. Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States. J Acquir Immune Defic Syndr. 2020 02 01; 83(2):148-156.
    View in: PubMed
    Score: 0.214
  14. High Medication Possession Ratios Associated With Greater Risk of Virologic Failure Among Youth Compared With Adults in a Nigerian Cohort. J Acquir Immune Defic Syndr. 2018 07 01; 78(3):322-328.
    View in: PubMed
    Score: 0.192
  15. Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India. AIDS Res Hum Retroviruses. 2018 06; 34(6):486-497.
    View in: PubMed
    Score: 0.190
  16. The patient-centered medical home: a reality for HIV care in Nigeria. Int J Qual Health Care. 2017 Oct 01; 29(5):654-661.
    View in: PubMed
    Score: 0.182
  17. Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study. Clin Infect Dis. 2017 Jun 01; 64(11):1612-1614.
    View in: PubMed
    Score: 0.178
  18. Barriers to Care and 1-Year Mortality Among Newly Diagnosed HIV-Infected People in Durban, South Africa. J Acquir Immune Defic Syndr. 2017 04 01; 74(4):432-438.
    View in: PubMed
    Score: 0.176
  19. Sizanani: A Randomized Trial of Health System Navigators to Improve Linkage to HIV and TB Care in South Africa. J Acquir Immune Defic Syndr. 2016 Oct 01; 73(2):154-60.
    View in: PubMed
    Score: 0.170
  20. Age Matters: Increased Risk of Inconsistent HIV Care and Viremia Among Adolescents and Young Adults on Antiretroviral Therapy in Nigeria. J Adolesc Health. 2016 09; 59(3):298-304.
    View in: PubMed
    Score: 0.167
  21. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. Clin Infect Dis. 2016 06 01; 62(11):1454-1462.
    View in: PubMed
    Score: 0.163
  22. Finding HIV in hard to reach populations: mobile HIV testing and geospatial mapping in Umlazi township, Durban, South Africa. AIDS Behav. 2015 Oct; 19(10):1888-95.
    View in: PubMed
    Score: 0.159
  23. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. AIDS. 2015 Jun 19; 29(10):1247-59.
    View in: PubMed
    Score: 0.156
  24. The lifetime medical cost savings from preventing HIV in the United States. Med Care. 2015 Apr; 53(4):293-301.
    View in: PubMed
    Score: 0.153
  25. The clinical role and cost-effectiveness of long-acting antiretroviral therapy. Clin Infect Dis. 2015 Apr 01; 60(7):1102-10.
    View in: PubMed
    Score: 0.151
  26. HIV cure strategies: how good must they be to improve on current antiretroviral therapy? PLoS One. 2014; 9(11):e113031.
    View in: PubMed
    Score: 0.149
  27. Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. PLoS One. 2014; 9(1):e85197.
    View in: PubMed
    Score: 0.141
  28. Validation and calibration of a computer simulation model of pediatric HIV infection. PLoS One. 2013; 8(12):e83389.
    View in: PubMed
    Score: 0.140
  29. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013 Oct 31; 369(18):1715-25.
    View in: PubMed
    Score: 0.139
  30. A randomized trial to optimize HIV/TB care in South Africa: design of the Sizanani trial. BMC Infect Dis. 2013 Aug 26; 13:390.
    View in: PubMed
    Score: 0.137
  31. Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India. PLoS One. 2013; 8(5):e64604.
    View in: PubMed
    Score: 0.135
  32. Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis. Antivir Ther. 2013; 18(1):45-55.
    View in: PubMed
    Score: 0.127
  33. Not all are lost: interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program. PLoS One. 2012; 7(3):e32993.
    View in: PubMed
    Score: 0.124
  34. Loss to follow-up and mortality among HIV-infected people co-infected with TB at ART initiation in Durban, South Africa. J Acquir Immune Defic Syndr. 2012 Jan 01; 59(1):25-30.
    View in: PubMed
    Score: 0.122
  35. Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. AIDS Res Ther. 2011 Mar 10; 8:14.
    View in: PubMed
    Score: 0.116
  36. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis. 2010 Oct 01; 51(7):823-9.
    View in: PubMed
    Score: 0.112
  37. The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat. 2011 Jul; 18(7):506-12.
    View in: PubMed
    Score: 0.110
  38. Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should. AIDS. 2010 Jan; 24 Suppl 1:S37-44.
    View in: PubMed
    Score: 0.106
  39. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. PLoS Med. 2009 Oct; 6(10):e1000173.
    View in: PubMed
    Score: 0.105
  40. Impact of select immunologic and virologic biomarkers on CD4 cell count decrease in patients with chronic HIV-1 subtype C infection: results from Sinikithemba Cohort, Durban, South Africa. Clin Infect Dis. 2009 Sep 15; 49(6):956-64.
    View in: PubMed
    Score: 0.104
  41. Improving outcomes in state AIDS drug assistance programs. J Acquir Immune Defic Syndr. 2009 Aug 15; 51(5):513-21.
    View in: PubMed
    Score: 0.104
  42. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr. 2009 Jun 01; 51(2):135-9.
    View in: PubMed
    Score: 0.102
  43. Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa. S Afr Med J. 2008 Mar; 98(3):204-8.
    View in: PubMed
    Score: 0.094
  44. The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean. J Acquir Immune Defic Syndr. 2007 Dec 01; 46(4):463-71.
    View in: PubMed
    Score: 0.092
  45. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med. 2007 Oct; 8(7):439-50.
    View in: PubMed
    Score: 0.091
  46. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis. 2007 Oct 15; 45(8):1062-70.
    View in: PubMed
    Score: 0.091
  47. HIV morbidity and mortality in Jamaica: analysis of national surveillance data, 1993--2005. Int J Infect Dis. 2008 Mar; 12(2):132-8.
    View in: PubMed
    Score: 0.090
  48. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS. 2007 Jul; 21 Suppl 4:S117-28.
    View in: PubMed
    Score: 0.090
  49. Response to "CD4 cell count natural history and informative censoring in sub-Saharan Africa". J Acquir Immune Defic Syndr. 2007 Apr 01; 44(4):491.
    View in: PubMed
    Score: 0.088
  50. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire. Antivir Ther. 2007; 12(4):543-51.
    View in: PubMed
    Score: 0.086
  51. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006 Nov; 44(11):990-7.
    View in: PubMed
    Score: 0.085
  52. Optimizing resource allocation in United States AIDS drug assistance programs. Clin Infect Dis. 2006 Nov 15; 43(10):1357-64.
    View in: PubMed
    Score: 0.085
  53. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med. 2006 Sep 14; 355(11):1141-53.
    View in: PubMed
    Score: 0.085
  54. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006 Aug 01; 42(4):464-9.
    View in: PubMed
    Score: 0.084
  55. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006 Jul 01; 194(1):11-9.
    View in: PubMed
    Score: 0.083
  56. Assessing the impact of federal HIV prevention spending on HIV testing and awareness. Am J Public Health. 2006 Jun; 96(6):1038-43.
    View in: PubMed
    Score: 0.083
  57. Therapeutic drug monitoring in HIV treatment: a literature review. HIV Clin Trials. 2006 Mar-Apr; 7(2):59-69.
    View in: PubMed
    Score: 0.082
  58. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005 Nov 01; 41(9):1316-23.
    View in: PubMed
    Score: 0.079
  59. Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts. Am J Public Health. 2005 Jan; 95(1):71-3.
    View in: PubMed
    Score: 0.075
  60. Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview. Clin Infect Dis. 2004 Jun 01; 38(11):1613-22.
    View in: PubMed
    Score: 0.072
  61. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003 Dec 01; 115(8):632-41.
    View in: PubMed
    Score: 0.070
  62. Acute human immunodeficiency virus infection in patients presenting to an urban urgent care center. Clin Infect Dis. 2003 Dec 15; 37(12):1699-704.
    View in: PubMed
    Score: 0.070
  63. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis. 2003 Mar 01; 36(5):652-62.
    View in: PubMed
    Score: 0.066
  64. Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis. Clin Infect Dis. 2003 Jan 01; 36(1):86-96.
    View in: PubMed
    Score: 0.065
  65. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther. 2002 Dec; 7(4):257-66.
    View in: PubMed
    Score: 0.065
  66. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr. 2002 Sep 01; 31(1):27-37.
    View in: PubMed
    Score: 0.064
  67. The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality. J Acquir Immune Defic Syndr. 2002 Aug 01; 30(4):421-8.
    View in: PubMed
    Score: 0.064
  68. Identifying undiagnosed human immunodeficiency virus: the yield of routine, voluntary inpatient testing. Arch Intern Med. 2002 Apr 22; 162(8):887-92.
    View in: PubMed
    Score: 0.062
  69. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med. 2002 Apr 22; 162(8):921-8.
    View in: PubMed
    Score: 0.062
  70. Clinical Impact, Costs, and Cost-effectiveness of Expanded Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Massachusetts. Clin Infect Dis. 2021 11 02; 73(9):e2908-e2917.
    View in: PubMed
    Score: 0.060
  71. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Public Health. 2001 Sep; 91(9):1456-63.
    View in: PubMed
    Score: 0.060
  72. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int J Epidemiol. 2001 Aug; 30(4):864-71.
    View in: PubMed
    Score: 0.059
  73. Investigation of primary human immunodeficiency virus infection in patients who test positive for heterophile antibody. Clin Infect Dis. 2001 Aug 15; 33(4):570-2.
    View in: PubMed
    Score: 0.059
  74. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001 Mar 20; 134(6):440-50.
    View in: PubMed
    Score: 0.058
  75. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001 Mar 15; 344(11):824-31.
    View in: PubMed
    Score: 0.058
  76. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. Clin Infect Dis. 2001 Mar 01; 32(5):783-93.
    View in: PubMed
    Score: 0.058
  77. Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa: a microsimulation modelling study. Lancet Glob Health. 2021 02; 9(2):e120-e129.
    View in: PubMed
    Score: 0.057
  78. Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa: a microsimulation modelling study. medRxiv. 2020 Oct 11.
    View in: PubMed
    Score: 0.056
  79. Clinical Impact, Costs, and Cost-Effectiveness of Expanded SARS-CoV-2 Testing in Massachusetts. medRxiv. 2020 Jul 24.
    View in: PubMed
    Score: 0.055
  80. Cost-effectiveness of a Medical Care Coordination Program for People With HIV in Los Angeles County. Open Forum Infect Dis. 2019 Dec; 6(12):ofz537.
    View in: PubMed
    Score: 0.053
  81. Using national laboratory data to assess cumulative frequency of linkage after transfer to community-based HIV clinics in South Africa. J Int AIDS Soc. 2019 06; 22(6):e25326.
    View in: PubMed
    Score: 0.051
  82. The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS. Int J Technol Assess Health Care. 1999; 15(3):531-47.
    View in: PubMed
    Score: 0.050
  83. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making. 1998 Apr-Jun; 18(2 Suppl):S93-105.
    View in: PubMed
    Score: 0.047
  84. The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. J Int AIDS Soc. 2018 03; 21(3):e25096.
    View in: PubMed
    Score: 0.047
  85. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998 Jan 14; 279(2):130-6.
    View in: PubMed
    Score: 0.046
  86. Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. JAMA Intern Med. 2017 11 01; 177(11):1613-1621.
    View in: PubMed
    Score: 0.046
  87. Clinic-Based Urinary Lipoarabinomannan as a Biomarker of Clinical Disease Severity and Mortality Among Antiretroviral Therapy-Naive Human Immunodeficiency Virus-Infected Adults in South Africa. Open Forum Infect Dis. 2017; 4(3):ofx167.
    View in: PubMed
    Score: 0.045
  88. Adolescent Linkage to Care After a Large-scale Transfer From a Hospital-based HIV Clinic to the Public Sector in South Africa. Pediatr Infect Dis J. 2017 03; 36(3):311-313.
    View in: PubMed
    Score: 0.044
  89. Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study. J Infect Dis. 2016 Dec 01; 214(11):1672-1681.
    View in: PubMed
    Score: 0.043
  90. Impact of Unplanned Care Interruption on CD4 Response Early After ART Initiation in a Nigerian Cohort. J Int Assoc Provid AIDS Care. 2017 Jan/Feb; 16(1):98-104.
    View in: PubMed
    Score: 0.043
  91. Survival benefits of antiretroviral therapy in Brazil: a model-based analysis. J Int AIDS Soc. 2016; 19(1):20623.
    View in: PubMed
    Score: 0.041
  92. High rates of unplanned interruptions from HIV care early after antiretroviral therapy initiation in Nigeria. BMC Infect Dis. 2015 Sep 30; 15:397.
    View in: PubMed
    Score: 0.040
  93. Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu-Natal. HIV Med. 2015 Nov; 16(10):640-4.
    View in: PubMed
    Score: 0.039
  94. Cost-effectiveness of genotype testing for primary resistance in Brazil. J Acquir Immune Defic Syndr. 2015 Feb 01; 68(2):152-61.
    View in: PubMed
    Score: 0.038
  95. The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis. PLoS Med. 2014 Sep; 11(9):e1001725.
    View in: PubMed
    Score: 0.037
  96. HIV testing rates, prevalence, and knowledge among outpatients in Durban, South Africa: Time trends over four years. Int J STD AIDS. 2015 Sep; 26(10):704-9.
    View in: PubMed
    Score: 0.037
  97. The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials. HIV Clin Trials. 2014 Sep-Oct; 15(5):185-98.
    View in: PubMed
    Score: 0.037
  98. The Linkage Outcomes of a Large-scale, Rapid Transfer of HIV-infected Patients From Hospital-based to Community-based Clinics in South Africa. Open Forum Infect Dis. 2014 Sep; 1(2):ofu058.
    View in: PubMed
    Score: 0.037
  99. Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire. J Acquir Immune Defic Syndr. 2014 Jul 01; 66(3):294-302.
    View in: PubMed
    Score: 0.036
  100. Development and validation of a computer-based algorithm to identify foreign-born patients with HIV infection from the electronic medical record. Appl Clin Inform. 2014; 5(2):557-70.
    View in: PubMed
    Score: 0.036
  101. Incidence of World Health Organization stage 3 and 4 events, tuberculosis and mortality in untreated, HIV-infected children enrolling in care before 1 year of age: an IeDEA (International Epidemiologic Databases To Evaluate AIDS) East Africa regional analysis. Pediatr Infect Dis J. 2014 Jun; 33(6):623-9.
    View in: PubMed
    Score: 0.036
  102. Development, calibration and performance of an HIV transmission model incorporating natural history and behavioral patterns: application in South Africa. PLoS One. 2014; 9(5):e98272.
    View in: PubMed
    Score: 0.036
  103. Diagnostic accuracy of a point-of-care urine test for tuberculosis screening among newly-diagnosed HIV-infected adults: a prospective, clinic-based study. BMC Infect Dis. 2014 Feb 26; 14:110.
    View in: PubMed
    Score: 0.036
  104. Routine HIV screening in Portugal: clinical impact and cost-effectiveness. PLoS One. 2013; 8(12):e84173.
    View in: PubMed
    Score: 0.035
  105. The survival benefits of antiretroviral therapy in South Africa. J Infect Dis. 2014 Feb 15; 209(4):491-9.
    View in: PubMed
    Score: 0.035
  106. Linkage to care following community-based mobile HIV testing compared with clinic-based testing in Umlazi Township, Durban, South Africa. HIV Med. 2014 Jul; 15(6):367-72.
    View in: PubMed
    Score: 0.035
  107. Factors associated with self-reported repeat HIV testing after a negative result in Durban, South Africa. PLoS One. 2013; 8(4):e62362.
    View in: PubMed
    Score: 0.033
  108. Risk factors for late-stage HIV disease presentation at initial HIV diagnosis in Durban, South Africa. PLoS One. 2013; 8(1):e55305.
    View in: PubMed
    Score: 0.033
  109. Depressive symptoms and their impact on health-seeking behaviors in newly-diagnosed HIV-infected patients in Durban, South Africa. AIDS Behav. 2012 Nov; 16(8):2226-35.
    View in: PubMed
    Score: 0.032
  110. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa. Clin Infect Dis. 2013 Feb; 56(4):587-97.
    View in: PubMed
    Score: 0.032
  111. Drug-resistant tuberculosis among HIV-infected patients starting antiretroviral therapy in Durban, South Africa. PLoS One. 2012; 7(8):e43281.
    View in: PubMed
    Score: 0.032
  112. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS. 2012 May 15; 26(8):987-95.
    View in: PubMed
    Score: 0.031
  113. The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. PLoS One. 2012; 7(4):e36001.
    View in: PubMed
    Score: 0.031
  114. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis. 2012 May; 54(10):1504-13.
    View in: PubMed
    Score: 0.031
  115. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One. 2012; 7(3):e32144.
    View in: PubMed
    Score: 0.031
  116. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS. 2012 Jan 02; 26(1):45-56.
    View in: PubMed
    Score: 0.031
  117. Medication possession ratio: predicting and decreasing loss to follow-up in antiretroviral treatment programs in Côte d'Ivoire. J Acquir Immune Defic Syndr. 2011 Jul 01; 57 Suppl 1:S34-9.
    View in: PubMed
    Score: 0.030
  118. Loss to follow-up in a community clinic in South Africa--roles of gender, pregnancy and CD4 count. S Afr Med J. 2011 Apr; 101(4):253-7.
    View in: PubMed
    Score: 0.029
  119. Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. J Acquir Immune Defic Syndr. 2011 Apr; 56(4):356-64.
    View in: PubMed
    Score: 0.029
  120. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS. 2011 Feb 20; 25(4):479-92.
    View in: PubMed
    Score: 0.029
  121. Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med. 2011 Feb; 12(2):97-108.
    View in: PubMed
    Score: 0.029
  122. Screening for acute HIV infection in South Africa: finding acute and chronic disease. HIV Med. 2011 Jan; 12(1):46-53.
    View in: PubMed
    Score: 0.029
  123. The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr. 2011 Jan 01; 56(1):26-35.
    View in: PubMed
    Score: 0.029
  124. Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa. Antivir Ther. 2011; 16(6):853-61.
    View in: PubMed
    Score: 0.029
  125. Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire. PLoS One. 2010 Oct 15; 5(10):e13414.
    View in: PubMed
    Score: 0.028
  126. Routine HIV screening in France: clinical impact and cost-effectiveness. PLoS One. 2010 Oct 01; 5(10):e13132.
    View in: PubMed
    Score: 0.028
  127. Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. PLoS One. 2010 Sep 16; 5(9).
    View in: PubMed
    Score: 0.028
  128. Assessing the performance of a computer-based policy model of HIV and AIDS. PLoS One. 2010 Sep 09; 5(9).
    View in: PubMed
    Score: 0.028
  129. Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. HIV Clin Trials. 2010 Sep-Oct; 11(5):248-59.
    View in: PubMed
    Score: 0.028
  130. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis. 2010 Aug 15; 51(4):392-400.
    View in: PubMed
    Score: 0.028
  131. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr. 2010 Jul; 54(3):258-68.
    View in: PubMed
    Score: 0.028
  132. Frequent HIV testing among participants of a routine HIV testing program. Virulence. 2010 Mar-Apr; 1(2):68-71.
    View in: PubMed
    Score: 0.027
  133. CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials. Antivir Ther. 2010; 15(3):351-61.
    View in: PubMed
    Score: 0.027
  134. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med. 2009 Aug 04; 151(3):157-66.
    View in: PubMed
    Score: 0.026
  135. HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies. J Acquir Immune Defic Syndr. 2009 Jul 01; 51(3):310-6.
    View in: PubMed
    Score: 0.026
  136. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009 Mar 15; 48(6):806-15.
    View in: PubMed
    Score: 0.025
  137. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther. 2009; 14(4):523-31.
    View in: PubMed
    Score: 0.025
  138. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008 Oct 01; 22(15):2025-33.
    View in: PubMed
    Score: 0.024
  139. Routine, voluntary HIV testing in Durban, South Africa: correlates of HIV infection. HIV Med. 2008 Nov; 9(10):863-7.
    View in: PubMed
    Score: 0.024
  140. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis. 2008 May 01; 197(9):1324-32.
    View in: PubMed
    Score: 0.024
  141. Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr. 2007 Oct 01; 46(2):181-6.
    View in: PubMed
    Score: 0.023
  142. Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Côte d'Ivoire: impact of alternative methods of CD4 count modelling. Eur J Epidemiol. 2007; 22(10):737-44.
    View in: PubMed
    Score: 0.023
  143. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS. 2007 May 11; 21(8):973-82.
    View in: PubMed
    Score: 0.022
  144. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis. 2007 Apr 15; 44(8):1115-22.
    View in: PubMed
    Score: 0.022
  145. Diagnostic tests in HIV management: a review of clinical and laboratory strategies to monitor HIV-infected individuals in developing countries. Bull World Health Organ. 2006 Jul; 84(7):581-8.
    View in: PubMed
    Score: 0.021
  146. Refusing HIV testing in an urgent care setting: results from the "Think HIV" program. AIDS Patient Care STDS. 2006 Feb; 20(2):84-92.
    View in: PubMed
    Score: 0.020
  147. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS. 2005 Aug 12; 19(12):1299-308.
    View in: PubMed
    Score: 0.020
  148. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr. 2005 May 01; 39(1):69-77.
    View in: PubMed
    Score: 0.019
  149. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med. 2005 Mar; 118(3):292-300.
    View in: PubMed
    Score: 0.019
  150. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med. 2005 Feb 10; 352(6):586-95.
    View in: PubMed
    Score: 0.019
  151. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients. Antivir Ther. 2005; 10(1):41-52.
    View in: PubMed
    Score: 0.019
  152. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med. 2002 Nov 25; 162(21):2478-86.
    View in: PubMed
    Score: 0.016
  153. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making. 2002 Jan-Feb; 22(1):27-38.
    View in: PubMed
    Score: 0.015
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.